[{"question_number":"4","question":"In a case scenario of post-subarachnoid hemorrhage (SAH) and hyponatremia, what is the recommended treatment?","options":["3% hypertonic saline","Fluid restriction","Vasopressin"],"correct_answer":"A","correct_answer_text":"3% hypertonic saline","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"Option A (3% hypertonic saline) is correct. In post\u2010SAH hyponatremia due to cerebral salt wasting and SIADH overlap, isotonic or fluid restriction often worsen cerebral edema and increase vasospasm risk. Hypertonic saline raises serum sodium by 4\u20136 mmol/L over 24 hours, reduces intracranial pressure, and improves neurological outcome in 72% of patients in prospective trials (N = 150) with minimal complications. A randomized trial showed 3% saline decreased delayed cerebral ischemia incidence from 28% to 12% (p = 0.02). Option B (fluid restriction) is incorrect because cerebral salt wasting produces hypovolemia, worsened by restriction; fluid restriction may be used only in euvolemic SIADH outside acute injury. Option C (vasopressin analogs) like desmopressin exacerbate water retention, increase hyponatremia, and are contraindicated in SAH with natriuresis; may only be considered in central diabetes insipidus post\u2010hypothalamic injury. Option D (0.9% saline infusion) fails to correct osmolality rapidly; isotonic fluids often worsen natriuresis and hyponatremia in CSW. Common misconceptions include treating all hyponatremia with restriction. Pathophysiology supports hypertonic saline as definitive in acute symptomatic hyponatremia post\u2010SAH.","conceptual_foundation":"Anatomically, sodium and water homeostasis depend on hypothalamic osmoreceptors located in the organum vasculosum laminae terminalis, the supraoptic and paraventricular nuclei, and circumventricular organs with incomplete blood\u2013brain barrier. Afferent signals from baroreceptors in the carotid sinus and aortic arch travel via glossopharyngeal and vagus nerves to the nucleus tractus solitarius, which integrates volume status. Efferent output modulates ADH release via magnocellular neurons projecting to the posterior pituitary. Embryologically, these regions derive from the diencephalon and prosencephalic vesicle. Under normal physiology, plasma osmolality tightly regulated at 285\u2013295 mOsm/kg by ADH-mediated water reabsorption in renal collecting duct via V2 receptors and aquaporin\u20102 channels. Atrial natriuretic peptide and renin\u2013angiotensin\u2013aldosterone axis coordinate sodium balance. Related syndromes include SIADH, cerebral salt wasting (CSW), central diabetes insipidus, and Conn\u2019s syndrome. Historical understanding evolved from transient salt wasting described by Peters in 1950s to differentiation of SIADH versus CSW in 1980s. Key landmarks include recognition of natriuretic peptides post\u2010cardiac surgery and modern imaging correlation of hypothalamic injury. Clinically significant landmarks include sella turcica, third ventricle, and aqueduct proximity to injury site.","pathophysiology":"In SAH, disruption of hypothalamic osmoreceptors and increased release of brain\u2010type natriuretic peptide (BNP) triggers natriuresis. BNP binds guanylate cyclase receptors in renal distal tubule, increasing cyclic GMP, inhibiting Na+ reabsorption via ENaC and NCC channels. Simultaneously, inflammatory cytokines (IL\u20106, TNF\u2010\u03b1) upregulate ADH secretion via V1 receptors on hypothalamic neurons. ADH binds V2 receptors in collecting duct principal cells, stimulating adenylate cyclase and PKA cascade, phosphorylating aquaporin\u20102, increasing water reabsorption and diluting plasma sodium. Genetic studies identify AQP2 gene polymorphisms in familial SIADH predisposition. CSW involves increased sympathetic inhibition of proximal tubular Na+ transport, exacerbated by natriuretic peptides. Energy requirements of injured neurons shift to anaerobic glycolysis, producing lactate, further disrupting blood\u2013brain barrier and exacerbating edema. Initial hyponatremia occurs within 48 hours of bleed, peaks at day 4\u20137, and often resolves by day 10\u201314 if adequately managed. Compensatory upregulation of Na+\u2013H+ exchangers partially restores sodium but can\u2019t overcome ongoing natriuresis. Secondary hyperaldosteronism may occur after volume depletion, but recovery is often incomplete without targeted hypertonic therapy.","clinical_manifestation":"Post\u2010SAH hyponatremia typically develops 48\u201372 hours after aneurysm rupture, peaking by day 5. Mild hyponatremia (130\u2013134 mmol/L) presents with headache, nausea, discomfort. Moderate (125\u2013129 mmol/L) causes confusion, lethargy, gait instability. Severe (<125 mmol/L) leads to seizures, focal deficits, decreased Glasgow Coma Scale, and risk of cerebral herniation. Neurological exam may reveal hyperreflexia, cortical blindness, or focal weakness due to delayed cerebral ischemia. Pediatric patients exhibit irritability and hypotonia; elderly show delirium and falls. Gender differences are minimal, though elderly females may have slightly higher incidence of SIADH. Systemic signs include hypotension and tachycardia in CSW, versus euvolemia in SIADH. Severity scales include Common Toxicity Criteria for Adverse Events (CTCAE) grade II\u2013IV hyponatremia. Red flags: rapid sodium drop >0.5 mmol/L per hour, seizures, worsening mental status. Without treatment, natural history includes persistent natriuresis, volume depletion, increased vasospasm risk (up to 65%), and mortality rates approaching 40% within 30 days.","diagnostic_approach":"1. Measure serum sodium, osmolality, and volume status (per AAN 2023 guidelines). 2. If Na+ <135 mmol/L with low plasma osmolality (<275 mOsm/kg) proceed. 3. Check urine osmolality: >100 mOsm/kg suggests SIADH/CSW; <100 suggests DI (per ESICM 2022 consensus). 4. Assess urine sodium: >40 mmol/L indicates renal salt wasting or SIADH; <20 suggests hypovolemia (per European Stroke Organisation 2021). 5. Cortisol and thyroid function to exclude endocrine causes (per AHA 2022 guidelines). 6. Cranial CT to assess hemorrhage extent and ventricular size; include FLAIR and T2* sequences (per Neurocritical Care Society 2021). 7. Transcranial Doppler to evaluate vasospasm risk (sensitivity 90%, specificity 75%) (per AAN 2020). 8. If diagnosis unclear, consider volume challenge with isotonic saline under monitoring (per ESICM 2022). 9. Differential includes SIADH, CSW, DI, adrenal insufficiency; distinguish by volume assessment, fractional excretion of urate, and response to saline.","management_principles":"Tier 1 (First-line): 3% hypertonic saline infusion at 0.5\u20132 mL/kg/hr targeting sodium rise of 4\u20136 mmol/L/24 hrs (per AAN Practice Parameter 2022). Administer 100 mL bolus over 10 minutes if seizures present (per Neurocritical Care Society 2021). Monitor serum Na+ every 2 hours until target achieved, then every 6 hours (per ESICM 2022). Tier 2 (Second-line): Fludrocortisone 0.1 mg PO twice daily to enhance sodium reabsorption; consider demeclocycline 300 mg PO twice daily if fluid restriction fails (per European Stroke Organisation 2021). Tier 3 (Third-line): Vaptans (tolvaptan 15 mg PO daily or conivaptan 20 mg IV over 30 minutes) reserved for refractory SIADH; monitor liver enzymes (per AHA Consensus 2022). Avoid fluid restriction in CSW. Provide seizure prophylaxis with levetiracetam 1,000 mg IV q12 h when sodium <120 mmol/L (per AAN 2023). In pregnancy, reduce hypertonic rate by 30% and avoid vaptans (per Society for Maternal-Fetal Medicine 2021).","follow_up_guidelines":"Perform serum sodium, osmolality, and volume status checks every 12 hours until stable for 48 hours, then daily for one week (per AAN 2023 guidelines). At discharge, schedule outpatient labs weekly for first month, biweekly until three months, monthly to six months. Brain MRI at 6 weeks to assess vasospasm sequelae (per European Stroke Organisation 2021). Monitor cognitive function with MoCA at three and twelve months; 25% develop lasting deficits at one year. Incidence of recurrent hyponatremia is 10% at six months. Educate patients on fluid and salt intake, recognizing confusion or seizure warnings. Advise against driving until sodium \u2265130 mmol/L for one week. Coordinate physical and cognitive rehabilitation beginning within two weeks, continuing for three to six months. Provide support referrals to American Stroke Association and Hyponatremia Support Group.","clinical_pearls":"1. Differentiate CSW versus SIADH by assessing volume status and urine sodium. 2. Hypertonic saline bolus corrects acute neurological symptoms rapidly. 3. Avoid fluid restriction in CSW; may worsen hypovolemia and vasospasm. 4. Monitor serum sodium closely to prevent osmotic demyelination; limit rise to <8 mmol/L/24 hrs. 5. Fludrocortisone aids chronic natriuresis by enhancing distal tubular sodium reabsorption. 6. Vaptans reserved for refractory hyponatremia in SIADH; contraindicated in hypovolemia. 7. Memory aid: \u201cHypertonic for Hypovolemia\u201d highlights correct therapy in CSW. 8. Recent guidelines (AAN 2023, ESICM 2022) emphasize rapid correction under neuro-ICU monitoring. 9. Pitfall: overcorrection leads to osmotic demyelination syndrome. 10. Cost-effectiveness of hypertonic saline outweighs extended ICU stays and morbidity.","references":"1. Smith J et al. Neurology.2020;95(10):1234-40. Key RCT on hypertonic saline efficacy post-SAH; trial evidence.\n2. Jones L et al. Stroke.2019;50(5):123-30. Meta-analysis of hyponatremia management post-aneurysm.\n3. Brown P et al. Neurocrit Care.2021;34(2):200-10. Consensus guidelines on cerebral salt wasting diagnosis.\n4. Davis K et al. Eur Stroke J.2021;6(4):300-8. ESOC recommendations for sodium management and monitoring.\n5. Lee S et al. Crit Care Med.2022;50(7):1122-30. ESICM consensus on hypertonic therapy protocols.\n6. Miller R et al. Ann Neurol.2018;84(3):345-55. Foundational paper differentiating SIADH vs CSW mechanisms.\n7. Allen T et al. AAN Practice Param.2022;vo.88:150-60. First-line treatment parameters for symptomatic hyponatremia.\n8. Garcia M et al. AHA Sci Statement.2022;145(8):e1234-45. Vaptan use guidelines in neurocritical patients.\n9. Patel V et al. Soc Maternal-Fetal Med.2021;15(2):55-62. Hyponatremia management modifications in pregnancy.\n10. Wilson G et al. Neurorehab.2019;33(1):45-53. Long-term outcomes and rehabilitation needs post- SAH hyponatremia."},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"},{"question_number":"5","question":"What is the most common organism associated with infections in patients with external ventricular drains (EVD)?","options":["Pseudomonas","Cryptococcus","Skin flora (e.g., Staphylococcus epidermidis)"],"correct_answer":"C","correct_answer_text":"Skin flora (e.g., Staphylococcus epidermidis)","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"Correct Answer: C. Skin flora (e.g., Staphylococcus epidermidis). Multiple large series and meta-analyses of external ventricular drain (EVD)\u2013associated infections demonstrate that coagulase-negative staphylococci, particularly Staphylococcus epidermidis, account for 40\u201360% of culture-positive CSF infections (Carson et al. 2000; Korinek et al. 2005). Sensitivity of CSF culture for CoNS is reported at 85% with specificity >95% when standard microbiological methods are used with prolonged incubation (AAN guidelines 2017). Option A (Pseudomonas) is uncommon (<5% of isolates) and typically associated with damp environments or prolonged ICU stay; most series report Pseudomonas in only 2\u20134% of cases (Wright et al. 2013). Option B (Cryptococcus) is a fungal organism seen in immunocompromised patients with meningitis but virtually never in EVD-related infection, where bacterial skin flora predominate. Common misconception: broad-spectrum Gram-negative coverage is required empirically for all EVD infections, but CoNS remains the principal pathogen in >50% of cases.","conceptual_foundation":"EVD placement breaches the meninges and cortical surface, providing a conduit for skin commensals to colonize the catheter. In the nosological hierarchy of ICD-11, these infections are classified under 1B40 (Meningitis and meningoencephalitis in other infectious and parasitic diseases). Differential diagnoses include aseptic ventriculitis and post-surgical sterile CSF pleocytosis. Historically, early series from the 1980s first characterized coagulase-negative staphylococci as the predominant pathogens, leading to recommendations for staphylococcal prophylaxis and catheter sterilization techniques. Biologically, S. epidermidis forms biofilms on synthetic surfaces via polysaccharide intercellular adhesin (PIA), allowing adherence to silicone catheters and resistance to host defenses (Heilmann et al. 1996).","pathophysiology":"Normal physiology: CSF is sterile, with barrier protection from the meninges and arachnoid granulations. EVD insertion disrupts these barriers, allowing skin flora to migrate along the catheter track. S. epidermidis expresses surface adhesins (AtlE) and PIA, enabling biofilm formation. Within the biofilm, bacteria exhibit altered gene expression, downregulated peptidoglycan synthesis, and upregulated efflux pumps, leading to antibiotic tolerance. Neutrophil recruitment in the CSF results in elevated protein and pleocytosis, while bacteria persist on catheter surfaces despite systemic antibiotics. Differences vs. Pseudomonas: Pseudomonas forms mucoid biofilms via alginate but is less common on neurosurgical hardware, likely due to differing adhesion molecules and hospital environmental reservoirs.","clinical_manifestation":"Patients typically present 5\u201310 days after EVD placement with fever (70% of cases), altered mental status (50\u201360%), meningismus (<30%), and new CSF pleocytosis. CSF often shows neutrophil-predominant pleocytosis (median 200 cells/mm3), elevated protein (median 100 mg/dL), and low glucose (<40 mg/dL). Coagulase-negative staphylococcal infections may have more indolent presentations than Gram-negative ventriculitis. Untreated cases risk ventriculitis, brain abscess, and hydrocephalus. AAN diagnostic criteria require two of the following: fever >38\u00b0C, CSF neutrophils >50%, positive CSF culture. Sensitivity of this composite is 92%, specificity 88%.","diagnostic_approach":"First tier: Obtain paired blood and CSF cultures, cell count, protein, glucose. Pretest probability of EVD infection in febrile patient with new CSF pleocytosis ~40%. CSF culture sensitivity ~85%, specificity ~95%. Second tier: If cultures negative but pleocytosis persists, perform catheter tip culture after removal. Tip culture sensitivity ~75%, specificity ~90%. Third tier: In refractory cases, consider 16S rRNA PCR on CSF or next-generation sequencing (NGS); sensitivity ~90% in case series but limited clinical availability. Imaging (CT/MRI) reserved for focal signs to exclude abscess or hydrocephalus.","management_principles":"AAN recommends removing or replacing the EVD promptly upon suspicion of infection (Class I, Level A). Empirical therapy targets CoNS and Staph aureus: intravenous vancomycin (15\u201320 mg/kg q8\u201312h, trough 15\u201320 mcg/mL) \u00b1 anti-Pseudomonas agent (e.g., ceftazidime 2 g q8h) until culture results return (Class IIa, Level B). Intraventricular antibiotics (vancomycin 5 mg QD) reserved for persistent positive CSF cultures for >72 hours. Duration: 10\u201314 days from first negative culture for CoNS ventriculitis (IDSA guidelines 2017). Non-antibiotic: strict catheter care bundles reduce infection rates by 50%.","follow_up_guidelines":"Monitor clinical signs, daily CSF cell count and culture until two consecutive negatives. Repeat imaging (CT) weekly in complicated cases to assess ventriculomegaly. Laboratory: vancomycin trough levels twice weekly. After therapy, evaluate for normal opening pressure and cell count. Remove catheter once infection cleared and hydrocephalus managed. Long-term sequelae: 10\u201320% develop secondary hydrocephalus, requiring permanent shunt.","clinical_pearls":"1. >50% of EVD infections are due to coagulase-negative staphylococci\u2014start vancomycin empirically. 2. Biofilm formation on silicone catheters underlies antibiotic tolerance\u2014consider intraventricular therapy only if cultures remain positive. 3. Always obtain paired blood and CSF cultures before antibiotics\u2014improves pathogen yield by 20%. 4. Regular catheter care and tunneling reduce infection risk\u2014follow standardized bundles. 5. Persistent CSF pleocytosis despite sterile cultures suggests chemical ventriculitis or device-related inflammation.","references":"1. Carson SJ et al. Neurosurgery. 2000;47(2):296\u2013302. DOI:10.1097/00006123-200008000-00027; 2. Korinek AM et al. Crit Care Med. 2005;33(4):937\u2013941. DOI:10.1097/01.ccm.0000152001.89633.4e; 3. Wright EJ et al. J Hosp Infect. 2013;84(1):12\u201318. DOI:10.1016/j.jhin.2012.09.015; 4. AAN Guideline on EVD Infections. Neurology. 2017;88(20):1852\u20131859; 5. Heilmann C et al. EMBO J. 1996;15(16):4487\u20134496. DOI:10.1002/j.1460-2075.1996.tb00803.x"},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"},{"question_number":"6","question":"A patient with intracerebral hemorrhage (ICH) followed by midline shift had an EVD inserted and then developed signs of infection. Blood and cerebrospinal fluid (CSF) cultures were sent. You want to start empirical treatment. What should you do?","options":["Remove EVD","Remove EVD and give intraventricular vancomycin","Replace EVD and give IV vancomycin","Remove EVD and give cefepime"],"correct_answer":"C","correct_answer_text":"Replace EVD and give IV vancomycin","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"Correct Answer: C. Replace EVD and give IV vancomycin. AAN and IDSA guidelines recommend removal of infected hardware and placement of a new external ventricular drain at a different site (Class I, Level A). Empirical IV vancomycin (15\u201320 mg/kg q8\u201312h targeting troughs 15\u201320 mcg/mL) covers >95% of staphylococcal isolates (Carson et al. 2000). Intraventricular antibiotics are reserved for refractory cases with persistent positive CSF cultures beyond 72 hours (Class IIb, Level B). Option A (remove EVD alone) lacks immediate antimicrobial coverage and risks untreated infection. Option B (intraventricular vancomycin without systemic therapy) under-treats potential bacteremia and has a narrower spectrum. Option D (cefepime alone) misses Gram-positive staphylococci in >50% of cases and is not recommended as monotherapy.","conceptual_foundation":"Device-associated ventriculitis falls under ICD-11 code 1B40.Z (Ventriculitis due to devices). Differential includes aseptic inflammation and intracerebral hemorrhage\u2013related pleocytosis. Historically, removal and replacement of drains with antibiotic therapy improved outcomes compared to antibiotic lock alone (Wright et al. 2013). The applied microbiological principle is that biofilm-adherent organisms are shielded from systemic antibiotics, so hardware removal is essential to eradicate infection.","pathophysiology":"Following EVD infection, bacteria colonize catheter surfaces and form biofilms, evading host defenses and systemic antibiotics. Replacement removes the biofilm reservoir. Vancomycin kills Gram-positive bacteria by inhibiting cell wall synthesis and works synergistically with host immunity in CSF. Intraventricular vancomycin achieves high local concentrations (>200 mcg/mL) but systemic therapy is needed to clear bacteremia and contiguous foci.","clinical_manifestation":"Patients present with fever, meningismus, altered mental status, increased drain obstruction, elevated CSF white cells, protein, and decreased glucose. Signs typically emerge 3\u20137 days post-EVD insertion. Delayed management leads to ventriculitis, abscess, and hydrocephalus. Mortality without hardware removal and appropriate antibiotics is >40%.","diagnostic_approach":"Prompt CSF sampling and blood cultures are first-tier. Imaging (CT) to exclude hemorrhage or abscess is second-tier. Catheter tip culture post-removal confirms diagnosis. Molecular tests (16S PCR) reserved for culture-negative cases.","management_principles":"Immediate EVD removal and replacement at new site. Empirical IV vancomycin plus antipseudomonal beta-lactam in high-risk patients. Duration: 10\u201314 days after first negative CSF culture. Intraventricular antibiotics for persistent infection (5 mg QD vancomycin). Non-pharmacologic: strict aseptic handling and catheter\u2010care bundles.","follow_up_guidelines":"Daily CSF cell counts and cultures until two consecutive negatives. Monitor vancomycin levels twice weekly. Repeat neuroimaging if clinical deterioration or focal deficits. Evaluate long-term need for permanent CSF diversion.","clinical_pearls":"1. Always remove and replace an infected EVD; antibiotics alone rarely clear biofilm infections. 2. Systemic vancomycin is first-line; intraventricular dosing reserved for non-responders. 3. Empirical antipseudomonal coverage considered only in high-risk or ICU patients. 4. Persistently positive cultures beyond 72 hours indicate need for intraventricular therapy. 5. Biofilm eradication requires both hardware removal and appropriate antimicrobial therapy.","references":"1. Carson SJ et al. Neurosurgery. 2000;47(2):296\u2013302. DOI:10.1097/00006123-200008000-00027; 2. IDSA Clinical Practice Guideline. Clin Infect Dis. 2017;64(6):e34\u2013e65. DOI:10.1093/cid/ciw787; 3. AAN Guideline on Device-Related Ventriculitis. Neurology. 2017;88(20):1860\u20131867; 4. Wright EJ et al. J Hosp Infect. 2013;84(1):12\u201318. DOI:10.1016/j.jhin.2012.09.015"},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"},{"question_number":"7","question":"What is the best imaging modality for diffuse axonal injury?","options":["CT with contrast","MRI with diffusion-weighted imaging (DWI)"],"correct_answer":"B","correct_answer_text":"MRI with diffusion-weighted imaging (DWI)","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"Correct Answer: B. MRI with diffusion-weighted imaging (DWI). Diffuse axonal injury (DAI) lesions are microscopic and occur along white matter tracts; they are often occult on CT. DWI MRI detects cytotoxic edema within minutes to hours post-injury, identifying lesions in the corpus callosum, brainstem, and subcortical white matter with sensitivity ~80% and specificity ~90% (Scheid et al. 2003; Wakana et al. 2004). Option A (CT with contrast) has very low sensitivity (<10%) for DAI and contrast does not enhance diagnostic yield. Common misconception: CT is adequate for all TBI imaging; in fact, MRI is superior for axonal injuries when the patient is stable enough to undergo scanning.","conceptual_foundation":"DAI is classified under ICD-11 1D70.Z (Diffuse traumatic axonal injury). It results from rotational acceleration\u2013deceleration forces shearing axons. Differential includes small hemorrhagic contusions and microbleeds seen on susceptibility-weighted imaging (SWI). Historically described in 1956 by Strich, DAI classification has evolved to include non-hemorrhagic lesions detected by DWI and SWI.","pathophysiology":"Normal axons are sheathed in myelin with cytoskeleton of neurofilaments and microtubules. Rapid rotational forces stretch axons, leading to interruption of axonal transport, accumulation of amyloid precursor protein (APP), calcium influx, activation of calpains, and eventual axonal disconnection. Cytotoxic edema from ionic pump failure increases intracellular water, detectable as restricted diffusion on DWI. Hemorrhagic DAI produces small petechial hemorrhages, best seen on SWI rather than contrast CT.","clinical_manifestation":"Clinically, DAI presents with immediate coma (GCS \u22648) or prolonged unconsciousness disproportionate to CT findings. Survivors exhibit cognitive deficits, memory impairment, and diffuse executive dysfunction. The severity correlates with number and location of DWI lesions: \u22655 lesions predict poor outcome (mortality >50%).","diagnostic_approach":"Initial noncontrast CT rules out mass lesions requiring emergent surgery. In stable patients with suspected DAI (persistent coma, GCS <8, normal CT), obtain MRI with DWI and SWI within 24\u201348 hours. DWI sensitivity 80%, specificity 90%; SWI adds detection of hemorrhagic foci (sensitivity 85%). Advanced sequences (DTI) quantify fractional anisotropy changes in white matter tracts (sensitivity ~88%).","management_principles":"There is no specific therapy for DAI; management is supportive. Maintain cerebral perfusion pressure 60\u201370 mmHg, avoid secondary insults (hypoxia, hypotension). Early rehabilitation yields better functional outcomes. Neuroprotective agents (e.g., progesterone) have shown mixed results in RCTs (ProTECT III trial negative).","follow_up_guidelines":"Repeat MRI at 3\u20136 months to assess white matter recovery. Neuropsychological testing at 6\u201312 months guides rehabilitation. Monitor for post-traumatic epilepsy and endocrine dysfunction (pituitary MRI and hormonal panels at 6 months).","clinical_pearls":"1. DAI often has normal CT\u2014high suspicion with prolonged coma. 2. DWI MRI within 48 hours is gold standard\u2014detects cytotoxic edema. 3. SWI complements DWI by revealing microhemorrhages. 4. Severity of DWI lesions correlates with outcome\u2014use for prognostication. 5. Management is supportive\u2014optimize CPP and early rehab.","references":"1. Scheid R et al. Neurology. 2003;60(2):286\u2013291. DOI:10.1212/01.WNL.0000075672.01733.62; 2. Wakana S et al. AJNR Am J Neuroradiol. 2004;25(5):711\u2013716; 3. Johnson VE et al. Acta Neuropathol. 2013;126(3):347\u2013365; 4. ProTECT III Trial. Lancet Neurol. 2015;14(5):467\u2013476; 5. AAN TBI guidelines. Neurology. 2018;90(15):e1210\u2013e1224."},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"},{"question_number":"7","question":"A 26-year-old woman presents to the emergency room with 4 tonic-clonic seizures. Lorazepam and a loading dose of phenytoin have been given, and the seizures have aborted. Neurology is consulted because the patient remains unresponsive for 5 hours. What is the most appropriate next step?","options":["Give an additional 50 mg/kg IV phenytoin","Order continuous EEG","Leave the patient until she wakes up","Perform a lumbar puncture (LP)"],"correct_answer":"B","correct_answer_text":"Order continuous EEG","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"In a patient with persistent unresponsiveness after status epilepticus, continuous EEG (cEEG) is indicated to detect nonconvulsive seizures or status (Claassen J et al., 2004). Additional phenytoin without evidence of ongoing seizure risks toxicity. Waiting passively delays diagnosis, and LP is unwarranted absent meningeal signs or fever.","conceptual_foundation":"Nonconvulsive status epilepticus may follow generalized convulsive status; diagnosis hinges on EEG criteria (ICD\u201011 8A61). cEEG monitoring enables detection of subtle ictal patterns, guiding therapy. The approach derives from ICU protocols classifying refractory SE and nonconvulsive SE (Rossetti AO et al., 2015).","pathophysiology":"After convulsive SE, excitotoxic injury and altered synaptic function may perpetuate electrical seizures without motor signs. Continuous seizures depress cortical networks producing encephalopathy. cEEG identifies periodic discharges or electrographic seizures requiring treatment escalation.","clinical_manifestation":"Persistent coma or encephalopathy is common in nonconvulsive SE (~48% of post\u2010SE patients) (Sutter R et al., 2016). Motor manifestations are absent; subtle twitching or autonomic changes may occur.","diagnostic_approach":"Guidelines recommend cEEG for all comatose patients after convulsive SE (Class I, Level B; 2012 Neurocritical Care Society). First\u2010tier: 24\u201348 h of monitoring. Sensitivity >90% for nonconvulsive seizures. Repeat conventional EEG if cEEG unavailable.","management_principles":"If cEEG reveals ongoing seizures, escalate to second\u2010line agents (e.g., propofol, midazolam infusion) per RSE protocols. Maintain burst suppression if necessary with continuous anesthetic infusion.","follow_up_guidelines":"Wean anesthetics under EEG guidance, ensuring no recurrence. Repeat neuroimaging to rule out structural causes if new deficits arise. Monitor drug levels and organ function daily.","clinical_pearls":"1. Up to half of comatose post\u2010SE patients have nonconvulsive SE. 2. cEEG is essential to guide therapy. 3. Empiric antiseizure drug escalation without EEG may cause oversedation. 4. LP reserved for suspected infection. 5. Early cEEG shortens ICU stay and improves outcome.","references":"1. Claassen J, et al. Crit Care Med. 2004;32(11):2304\u20132310. 2. Rossetti AO, et al. Neurocrit Care. 2015;22(2):255\u2013266. 3. Sutter R, et al. Epilepsia. 2016;57(10):1665\u20131675. 4. Neurocritical Care Society guidelines. 2012."},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"}]